dc.contributor.author | Uzbay, Tayfun | |
dc.contributor.author | Goktalay, Gokhan | |
dc.contributor.author | Kayir, Hakan | |
dc.contributor.author | Eker, Salih S. | |
dc.contributor.author | Sarandol, Asli | |
dc.contributor.author | Oral, Sema | |
dc.contributor.author | Buyukuysal, Levent | |
dc.contributor.author | Ulusoy, Gokhan | |
dc.contributor.author | Kirli, Selcuk | |
dc.date.accessioned | 2014-10-20T12:09:22Z | |
dc.date.available | 2014-10-20T12:09:22Z | |
dc.date.issued | 2013-04-02 | |
dc.identifier.citation | Uzbay, T., Goktalay, G., Kayir, H., Eker, S.S., Sarandol, A., Oral, S., Buyukuysal, L., Ulusoy, G., Kirli, S. Increased plasma agmatine levels in patients with schizophrenia. Journal of Psychiatric Research, 47: 1054-1060, 2013. | tr_TR |
dc.identifier.uri | http://earsiv.uskudar.edu.tr/xmlui/handle/123456789/305 | |
dc.identifier.uri | http://www.ncbi.nlm.nih.gov/pubmed/23664672 | |
dc.description.abstract | Agmatine is an endogenous substance, synthesized from L-arginine, and it is proposed to be a new
neurotransmitter. Preclinical studies indicated that agmatine may have an important role in the pathophysiology
of schizophrenia. This study was organized to investigate plasma agmatine in patients with
schizophrenia and in healthy controls. Eighteen patients with schizophrenia and 19 healthy individuals
constituted the subjects. Agmatine levels in the plasma were measured using the HPLC method. The
S100B protein level, which is a peripheral biomarker for brain damage, was also measured using the
ELISA method. While plasma levels of agmatine in patients with schizophrenia were significantly
increased (p < 0.0001) compared to those of healthy individuals (control), there were no significant
changes in the levels of S100B protein (p ¼ 0.660). An ROC (receiver operating characteristic) curve
analysis revealed that measuring plasma agmatine levels as a clinical diagnostic test would significantly
differentiate between patients with schizophrenia and those in the control group (predictive value:
0.969; p < 0.0001). The predictive value of S100B measurements was not statistically significant
(p > 0.05). A multiple regression analysis revealed that the age of the patient and the severity of the
illness, as indicated by the PANSS score, significantly contributed the plasma agmatine levels in patients
with schizophrenia. These results support the hypothesis that an excess agmatine release is important in
the development of schizophrenia. The findings also imply that the plasma agmatine level may be a
potential biomarker of schizophrenia. | tr_TR |
dc.language.iso | eng | tr_TR |
dc.relation.ispartofseries | SCI; | |
dc.relation.isversionof | 10.1016/j.jpsychires.2013.04.004 | tr_TR |
dc.subject | Agmatine Polyamines S100B Schizophrenia Biomarker | tr_TR |
dc.title | Increased plasma agmatine levels in patients with schizophrenia | tr_TR |
dc.type | Article | tr_TR |
dc.relation.journal | Journal of Psychiatric Research | tr_TR |
dc.contributor.department | Üsküdar Üniversitesi, Mühendislik ve Doğa Bilimleri Fakültesi, Moleküler Biyoloji ve Genetik | tr_TR |
dc.contributor.authorID | TR12488 | tr_TR |